SGLT2 versus DPP4 inhibitors for type 2 diabetes (Q44893360)

7 December 2017

title

SGLT2 versus DPP4 inhibitors for type 2 diabetes (English)

1 reference

7 December 2017

1 reference

André J Scheen

1

1 reference

7 December 2017

publication date

9 September 2013

1 reference

The Lancet: Diabetes & Endocrinology

7 December 2017

published in

1 reference

7 December 2017

volume

1

1 reference

7 December 2017

issue

3

1 reference

7 December 2017

page(s)

168-170

1 reference

A review of gliptins in 2011.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970095-0

7 January 2021

10.1016/S2213-8587(13)70095-0

Identifiers

DOI

1 reference

7 December 2017

1 reference